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(57) ABSTRACT
The present disclosure describes compositions providing for
controlled release of nitric oxide (NO) and methodsfor pro-
duction of these compositions. In some embodiments, the
compositions may include a biodegradable polymer and a
nitric oxide-releasing material at least partially encapsulated
by the biodegradable polymer. Nitric oxide-releasing materi-
als may include, for example, diazeniumdiolates and nitric
oxide contained within a zeolite, metal-organic framework or
other porous material. In general, the compositions are spun
into a porousfiber, which maybe further annealed by heating
in order to densify the fiber. Annealing may prolong the NO
release profile. Medical devices containing the compositions
described herein are also contemplated by the present disclo-
sure. Medical devices include, for example, textiles, ban-
dages andarticles of clothing.
22 Claims, 7 Drawing Sheets
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COMPOSITIONS AND MEDICAL DEVICES
FOR CONTROLLED RELEASE OF NITRIC
OXIDE AND METHODS OF PRODUCTION
THEREOF
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claimspriority to U.S. provisional patent
application 61/164,769,filed Mar. 30, 2009, which is incor-
porated by reference herein in its entirety.
STATEMENT REGARDING
FEDERALLY-SPONSORED RESEARCH
Notapplicable.
BACKGROUND
Nitric oxide (NO)has long beenestablished as a signaling
molecule that promotes relaxation of smooth muscle cells.
Morerecently, it has been established that NO can mediate
other biological processes and diseases including, for
example, wound healing, inflammation, plant disease resis-
tance, sexual dysfunction, social dysfunction, cancer, coro-
nary heart disease, restenosis, hypertension and angiogensis.
The implication of NO in so many biological processes and
diseases has stimulated interest in its exogenous delivery.
However, NO is a diatomic free radical, and its exogenous
delivery as a gasto biological systems has proved impractical
dueto its high reactivity.
A numberof systems have been proposedandtested for in
situ generation and delivery of NO. Such systems include
chemical compounds such as, for example, diazeniumdi-
olates and S-nitrosothiols. Other examples include, NO-re-
leasing gold nanoparticles, NO-releasing polyethyleneimine
(PEI) fibers and NO-releasing zeolites. Diazeniumdiolates
and zeolites are materials that hold particular promise for in
situ generation ofNO. However, neither ofthese systems has
yet been successfully implemented in a controlled-release
formulation that provides a sustained generation ofNO over
an extended period. Further, efforts to formulate diazenium-
diolates within a polymer matrix have been hampered by
leaching of these hydrophilic molecules from the matrix.
Leached diazeniumdiolates may becometoxic in vivo due to
metabolic conversion to N-nitrosamines, which are poten-
tially carcinogenic materials.
Zeolites are open, stable, three-dimensional microporous
aluminosilicates composedoforderedtetrahedra ofAIO, and
Si0,,. These materials have experienced a growinginterest for
biomedical applications. Zeolites are the aluminosilicate
members of the family of microporous solids known as
“molecularsieves.” With regardto in situ delivery ofNO,they
have shown exceptional promisefor their ability to store and
reversibly release NO from their microporousstructure. In
spite of their ability to readily store NO, application of NO-
loaded zeolites and other porous materials as a free powderto
biological systems is generally not considered practical.
In view of the foregoing, new biocompatible systems for
controlled or sustained release ofNO would be of substantial
benefit. Desirably, such systems would promote controlled or
sustained release ofNO to exploit the desirable properties of
NOin biological systems, while at the same time minimizing
the toxicity or biological incompatibility ofthe NO-releasing
material. Biocompatible systems for controlled or sustained
release of NO may be incorporated into medical devices as
described herein.
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SUMMARY
In various embodiments, the present disclosure describes
compositions for controlled release ofnitric oxide. The com-
positions include a biodegradable polymerand a nitric oxide-
releasing material at least partially encapsulated by the bio-
degradable polymer.
In other various embodiments, compositions for controlled
release ofnitric oxide include a biodegradable polymer and a
nitric oxide-releasing material at least partially encapsulated
by the biodegradable polymer. The nitric oxide-releasing
material is nitric oxide contained within a porous material.
The porous material may be, for example, a zeolite, metal-
organic framework or mesoporous molecularsieve.
Examples of mineral zeolites include, for example, anal-
cime (NaAISi,0,;.H,O), chabazite [(Ca,Na,,K,,Mg)
Al,S1,0,5.6H,O], clinoptilolite [(Na,K,Ca),_,Al,(Al,Si),
S$i,3;03,.12(H,O)], heulandite =[(Ca,Na),_,AI,(Al,Si),
Si, 3;03,.12H,O], natrolite (Na,Al,Si,0,5.2H,O), phillipsite
[(Ca,Na,,K,)3;A1,S1, 9035.12H,O], and stilbite
(NaCa,Al,Si,,03,.14H,O). Examples of mesoporous
molecular sieves include, for example, MCM-41 and SBA-
15. By virtue of their porous structure, zeolites can accom-
modate a wide variety ofcations, suchas Na*, K*, Ca?*, Mg?*
and others. These positive ionsare rather loosely held and can
readily be exchangedfor other cations in a contactsolution.In
certain embodiments herein, metal-exchanged zeolites may
be usedas the porous material, wherein the metalis a transi-
tion metal. Preferred transition metals include, but are not
limited to, Ti, V, Mn, Fe, Co, Cr, Zr, Nb, Mo, and W.
The porous material can also be a metal-organic frame-
work (MOF), which is a crystalline compound containing
metal ionsor clusters coordinated to often rigid organic mol-
ecules to form one-, two-, or three-dimensionalstructures that
can be porous. A metal-organic framework (MOF) is com-
posed of a metal ion or cluster of metal ions and an organic
molecule called a linker. The choice of metal and linker has
significant influence on the structure and properties of the
MOFin that the metal’s coordination preference influences
the size and shape ofpores by dictating how manyligands can
bind to the metal and in whichorientation. Example ofMOFs
include, for example, carboxylate-based MOFs, heterocyclic
azolate-based MOFs, metal-cyanide MOFs,covalent organic
frameworks and zeolite imidazolite frameworks.
In certain embodiments, S-nitrosothiol compounds encap-
sulated in zeolites canbe used as the source ofNO,rather than
adsorbed NO gas.S-nitrosothiols are a group of NO donors
that can be designed to release NO at varying rates. The
infinite flexibility ofNO release from porous materials such
as zeolites, mesoporous molecular sieves and metal-organic
frameworks allows the development of a wide range of dif-
ferent NO donor materials.
In some embodiments, the present disclosure includes
methods for preparing compositions for controlled release of
nitric oxide. The methods include providing a polymersolu-
tion of a biodegradable polymer dissolvedin a solvent; dis-
persing a nitric oxide-releasing material into the polymer
solution; and electrospinning the polymersolutioninto a fiber
containing pores.
In other various embodiments, the methods for preparing
compositions for controlled release of nitric oxide include
providing a polymer solution of a biodegradable polymer
dissolved in a solvent; dispersing a porous material in the
polymersolution; electrospinning the polymersolution into a
fiber containing pores; and impregnating the porous material
with nitric oxide. The porous material may be, for example, a
zeolite or a metal-organic framework. In some embodiments,
US 9,216,198 B2
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the methods further include annealing the fiber by heating
after impregnating the zeolite with nitric oxide.
In still other various embodiments, the present disclosure
describes medical devices containing compositions for con-
trolled release ofnitric oxide.
The foregoing has outlined rather broadly the features of
the present disclosure in order that the detailed description
that follows may be better understood. Additional features
and advantagesofthe disclosure will be described hereinaf-
ter, which form the subject of the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
For a more complete understanding of the present disclo-
sure, and the advantagesthereof, reference is now madeto the
following descriptions to be taken in conjunction with the
accompanying drawings describing specific embodiments of
the disclosure, wherein:
FIG. 1 showsthe structure of Zeolite-A;
FIG. 2 showsanillustrative schematic demonstrating the
manner in which poly(lactic acid) may buffer an aqueous
solution during nitric oxide release from a diazeniumdiolate;
FIG. 3A showsan illustrative schematic ofa standard elec-
trospinning process in whicha nitric oxide-releasing material
is dispersed in a biodegradable polymer; FIG. 3B shows an
illustrative schematic ofa concentric electrospinning process
in which an interiorfiber containing a biodegradable polymer
and a nitric oxide-releasing material is coated with a polymer
layer not containing the nitric oxide-releasing material;
FIG. 4A showsan illustrative SEM image of cobalt (1I)-
exchanged Zeolite-A; FIG. 4B showsan illustrative SEM
image of cobalt (I])-exchanged nanoscale Zeolite-A;
FIG. 5 showsanillustrative SEM image of a cobalt (II)-
exchanged Zeolite-A-containing fiber;
FIG. 6 showsanillustrative EDAX silicon map showing
that the zeolite particles are well dispersed throughout a
cobalt (I])-exchanged Zeolite-A-containingfiberwith little to
no particle aggregation;
FIG. 7 showsanillustrative image of a bandage formed
from a plurality of cobalt (II)-exchanged Zeolite-A-contain-
ing fibers;
FIG.8 showsanillustrative cross-sectional SEM image of
a cobalt (I])-exchanged Zeolite-A-containing fiber following
NO loading and annealing;
FIG. 9A shows an illustrative NO release profile from
NO-loaded cobalt (I])-exchanged Zeolite-A; FIG. 9B shows
an illustrative NO releaseprofile from NO-loaded cobalt (II)-
exchanged nanoscale Zeolite-A;
FIG. 10 showsillustrative NO release profiles from non-
annealed, porous fibers containing cobalt (II)-exchanged
Zeolite-A and cobalt (I])-exchanged nanoscale Zeolite-A;
FIGS. 11A and 11B show illustrative NO release profiles
from annealed fibers containing cobalt (I])-exchanged Zeo-
lite-A and cobalt (II)-exchanged nanoscale Zeolite-A;
FIG. 12 showsahistogram showinganillustrative decrease
in NO loadingin cobalt (1])-exchanged Zeolite-A-containing
fibers annealed at 65° C. and 85° C.;
FIG. 13 showsan illustrative SEM imageofas-synthesized
copper (II) biphenyl-4,4'-dicarboxylic acid triethylenedi-
amine metal-organic framework;
FIG. 14 showsan illustrative SEM imageofa fiber con-
taining copper (II) biphenyl-4,4'-dicarboxylic acid triethyl-
enediamine metal-organic framework nanocrystals;
FIG. 15 showsillustrative comparative NOreleaseprofiles
for non-annealed fibers containing copper(II) bipheny]-4,4'-
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dicarboxylic acid triethylenediamine metal-organic frame-
work nanocrystals and cobalt (II)-exchanged nanoscale Zeo-
lite-A; and
FIG. 16 showsa plot demonstrating an illustrative increase
in coronary flow following exposureofthe heart to the nitric
oxide-releasing bandage.
DETAILED DESCRIPTION
In the following description, certain details are set forth
such as specific quantities, sizes, etc. so as to provide a thor-
ough understanding of the present embodiments disclosed
herein. However, it will be evidentto those ofordinary skill in
the art that the present disclosure may be practiced without
such specific details. In many cases, details concerning such
considerations and the like have been omitted inasmuch as
such details are not necessary to obtain a complete under-
standing ofthe present disclosure and are within the skills of
persons of ordinary skill in the relevantart.
Referring to the drawings in general, it will be understood
thatthe illustrations are for the purpose ofdescribing particu-
lar embodiments of the disclosure and are not intended to be
limiting thereto. Drawings are not necessarily to scale.
While mostofthe terms used herein will be recognizable to
those of ordinary skill in the art, it should be understood,
however, that when not explicitly defined, terms should be
interpreted as adopting a meaning presently accepted by
those of ordinary skill in the art. In cases where the construc-
tion of a term would render it meaningless or essentially
meaningless, the definition should be taken from Webster’s
Dictionary, 3rd Edition, 2009. Definitions and/or interpreta-
tions should not be incorporated from other patent applica-
tions, patents, or publications, related or not, unless specifi-
cally stated in this specification or if the incorporation is
necessary for maintaining validity.
Asused herein, the term “biodegradable polymer”refers
to, for example, a polymer whichatleastpartially degrades to
its constituent monomers when exposed to aqueous condi-
tions.
Asused herein, the term “nitric oxide-releasing material”
refers to, for example, a material thateither releases adsorbed
or occluded nitric oxide upon exposure to specified condi-
tions or releases nitric oxide through a chemical reaction
upon exposure to specified conditions.
As used herein, the term “medical device” refers to, for
example, any device used either internally or externally for
treating, mediating, curing or alleviating a condition in a
patient or any device used as part of a medical procedure.
Mammalian cells synthesize NO using a two-step enzy-
matic process that oxidizes L-arginine to N-omega-hydroxy-
L-arginine, which is subsequently converted into L-citrulline
and anunchargedNO free radical. Three differentnitric oxide
synthase enzymes regulate NO production. Neuronalnitric
oxide synthase (NOS1 or nNOS)is formed within neuronal
tissue and plays a role in neurotransmission. Endothelial
nitric oxide synthase (NOS3 or eNOS)is secreted by endot-
helial cells and induces vasodilatation. Inducible nitric oxide
synthase (NOS2 or iNOS)is principally found in macroph-
ages, hepatocytes and chondrocytes and is associated with
immunecytotoxicity. Neuronal NOSand eNOSare constitu-
tive enzymes that regulate the rapid, short-term release of
small amounts ofNO.In these minute amounts NO activates
guanylate cyclase, which elevates cyclic guanosine mono-
phosphate (cGMP) concentrations, which in turn increase
intracellular Ca?* levels. Increased intracellular Ca?* levels
result in smooth muscle relaxation and vasodilation effects.
US 9,216,198 B2
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Inducible NOS is responsible for the sustained release of
larger amounts ofNO andis activated by extracellular factors
including endotoxins and cytokines. These higher NO levels
play a role in cellular immunity.
Nitric oxide’s therapeutic potential has been studied in a
numberofdiverse clinical indications including, for example,
cancer, coronary artery heart disease, restenosis, hyperten-
sion, angiogenesis, sexual dysfunction and social dysfunc-
tion. Moreover, recent studies have demonstrated that NO
also possesses considerable in vivo and ex vivo antimicrobial
activity, suggesting a possible role in treating infectious dis-
eases and fungal infections. The role ofNO in woundhealing
and general inflammation has also been studied.
Another postulated clinical role of NO is in the field of
organ transplantation, particularly heart transplantation. One
of the majorfactors in realizing a successful heart transplan-
tation is adequate organ preservation during the procurement,
storage, and implantation stages of a transplant. Currently,
organ preservation is based on a single flush induction of
cardioplegia and hypothermic storage in a solution. While
this methodis effective, time is still the major factor in heal-
ing, becausetheheart can only tolerate 4-5 hours ofischemia.
Prolonged periods of ischemia lead to increased acute and
chronic organ failure due to vasoconstriction and endothe-
lium damageofthe arteries upon a decrease in NO produc-
tion.
Attempts to mimic the natural release ofNO produced by
NOSenzymeshaveyet to be successful. Embodiments ofthe
present disclosure seek to provide compositions permitting
the controlled or sustained release ofNO in a mannerthatis
substantially non-toxic to biological systems and/or success-
fully mimicsthe natural enzymatic release ofNO.In view of
the established role of NO in so manybiological processes,
such compositions would demonstrate substantial utility in
the art. Medical devices and other therapeutic devices that
contain such compositions are also contemplated herein.
In various embodiments, the present disclosure describes
compositions for controlled release ofnitric oxide. The com-
positions include a biodegradable polymerand a nitric oxide-
releasing material at least partially encapsulated by the bio-
degradable polymer.
Thenitric oxide-releasing material maybeeither a material
that releases adsorbedor occludednitric oxide upon exposure
to specified conditions or a material that releases nitric oxide
through a chemical reaction upon exposure to specified con-
ditions. Nitric oxide may be released from such compounds
under physiological conditions, including exposure to an
aqueous environment. Nitric oxide release may also occur
through biochemical processes mediated by enzymes and
co-factors. For enzymatic conversion, enzymelevels and co-
factors required to stimulate NO production are often
depleted after repeat usage, and there is typically a physi-
ological recovery window ofabout 10 to 12 hours for admin-
istration of such enzymatically-activated compounds.
Nitric oxide-releasing materials that produce nitric oxide
through a chemical reaction may be considered nitric oxide
prodrugs. Nitric oxide prodrugs mayinclude, for example,
organic N-nitro and N-nitroso compounds(for example,dia-
zeniumdiolates), organic O-nitro and O-nitroso compounds
(for example, glyceryl trinitrate and amyl nitrite), organic
C-nitro and C-nitroso compounds (for example, nitrolipids,
nitronic acids, nitroalkanes, diazetine dioxides and furoxans),
S-nitrosophenols, S-nitrosothiols, N-hydroxyurea and
derivatives, N-hydroxyguanidine and derivatives, and nitro-
prusside ion and other metal nitrosyl complexes.
Amongthese nitric oxide-releasing materials, diazenium-
diolates are the most extensively studied. The general struc-
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tural formula of diazentumdiolates is exemplified by struc-
ture I below, where R and R'are independently H oranyalkyl,
alkenyl, alkynyl, aryl, aralkyl, alkaryl group or substituted
derivative thereof. Charge balance is generally affected by a
monovalent cation such as, for example, a Na* cation.
Oo 0\ +fN=N
NRR'
Diazeniumdiolates have half-lives for NO release generally
ranging from about 2 secondsto about 20 hours depending on
their R and R' substitution. NO release is stimulated by the
exposure of the diazeniumdiolate to protic conditions. In
various embodiments of the present disclosure, the nitric
oxide-releasing material is a diazeniumdiolate.
In other various embodimentsofthe present disclosure, the
nitric oxide-releasing material is a material that releases
adsorbed or occludednitric oxide upon exposure to specified
conditions. Materials meeting this criterion include porous
materials such as, for example, zeolites, metal-exchanged
zeolites, metal-organic frameworks, and mesoporous
molecular sieves.
Zeolites have shown the capability to reversibly bind and
release NO. Zeolite-A (also knownin the art as LTA zeolite),
in particular, has shown a particular capability for facile
adsorption andrelease ofnitric oxide. FIG. 1 showsthestruc-
ture of Zeolite-A. The structure includes channels having an
opening ofabout4 A in width. Exchangeable Natcations (not
shown)are found within the channels ofthe zeolite structure.
Nitric oxide adsorption may be improvedbyaltering the type
and amountof cations contained within the zeolite structure.
Suitable cations may be introduced through a simple ion
exchange with the Na* cations in the channels. In various
embodiments, the metal exchangedfor the Na* cation may be
a transition metal or lanthanide metal. Co (])-exchanged
Zeolite-A is particularly efficacious at adsorbing nitric oxide,
with a maximum adsorption capacity of about 1.7 mmol
NO/g zeolite. Nitric oxide release may be affected by expo-
sure ofthe NO-containing zeolite to atmospheric moisture or
water. In various embodiments of the present compositions,
the nitric oxide-releasing material is nitric oxide contained
within a zeolite. In some embodiments, the zeolite is Zeolite-
A. In some embodiments,the zeolite is cobalt (II)-exchanged
Zeolite-A. One of ordinary skill in the art will recognize that
any zeolite or metal-exchanged zeolite that reversibly binds
NO may be used equivalently within the spirit and scope of
the present disclosure.
In some embodiments, the porous, nitric oxide-releasing
material may be a metal-organic framework. An illustrative
metal-organic framework for reversible binding of NO
described herein is a copper (II) biphenyl-4,4'-dicarboxylic
acid triethylenediamine metal-organic framework nanocrys-
tals. Metal-organic frameworks also include zeolite-imida-
zolate MOFs, carboxylate-based MOFs, heterocyclic
azolate-based MOFs, metal-cyanide MOFs, and covalent
organic frameworks
In addition to the aforesaid embodiments, porous materials
may also contain compoundsoperable for release of nitric
oxide. In such embodiments, the porous materials release
nitric oxide through a chemical reaction rather than through
release of adsorbed nitric oxide. In an embodiment, a S-ni-
US 9,216,198 B2
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trosothiol or a metal nitrosyl complex may be housed within
a porous material such as a zeolite or a metal-organic frame-
work material.
Biodegradable polymers suitable for the compositions of
the present disclosure are not particularly limited. Such bio-
degradable polymers may include any polymerthatat least
partially depolymerizes under physiological or aqueous con-
ditions. Illustrative biodegradable polymers include, for
example, poly(lactic acid) (D and L forms), polycaprolac-
tone, poly(glycolic acid), polylactide (PLA), polydioxanone,
polyglycolide (PGA), polyanhydrides, polyorthoesters, poly
(amino acids), chitosans and sulfonated chitosan. Mixtures of
biodegradable polymers and various co-polymersofthe bio-
degradable polymers are also included within the spirit and
scope of the present disclosure. Naturally-occurring biode-
gradable polymers may include, for example, reconstituted
collagen, starch, or natural silks. Water-soluble polymers
such as, for example, poly(vinyl pyrrolidone) (PVP), poly
(ethylene oxide) (PEO), poly(vinyl alcohol) (PVA), and poly
(acrylic acid) (PAA) may be mixed with the aforesaid biode-
gradable polymers in various embodiments of the present
disclosure. The amountofwater-soluble polymer mixed with
the biodegradable polymer may range from about 1% by
weight to about 99% by weight.
In various embodiments of the compositions described
herein, the biodegradable polymer is poly(lactic acid). Poly
(lactic acid) is a known constituent of drug delivery compo-
sitions and is considered to be non-toxic. Its hydrolysis prod-
uct, lactic acid, is commonly produced in mammalian
organisms. Further, poly(lactic acid) has also been implicated
to facilitate transepidermaldelivery of drugs. Hence, compo-
sitions ofthe present disclosure maybe usedeither internally
or externally for delivery ofnitric oxide to a target tissue. The
above advantagesofpoly(lactic acid) notwithstanding, one of
ordinary skill in the art will recognize that any biodegradable
polymerhaving suitable properties may be used in the various
embodiments of the present disclosure, and the aforesaid
listing of biodegradable polymers should not be construed as
limiting of the scope of the present disclosure.
In various embodiments of the compositions described
herein, the biodegradable polymer contains pores. In some
embodiments, a portion of the composition contains pores
and the remainderofthe composition does not contain pores.
In other embodiments, the entire composition is substantially
porous. In some embodiments,at least a portion of thenitric
oxide-releasing material is located within the pores. In some
embodiments, the pores form a tortuous pathway within the
composition. Such tortuous pathways limit the accessibility
of moisture and chemical reagents to interior portions of the
compositions, thereby slowing the release of nitric oxide
from thenitric oxide-releasing materials contained therein. In
some embodiments, the nitric oxide-releasing material
located within the poresis a diazentumdiolate. Advantages of
a diazeniumdiolate at least partially encapsulated within the
pores of biodegradable polymerare discussed hereinafter.
In various embodiments of the compositions described
herein, the biodegradable polymeris spun intofibers. A plu-
rality of the fibers may be combined, spun or assembledinto
a free-standing paper or fabric. In some embodiments, the
fibers have diameters ranging from about 100 nm to about 25
um.In other embodiments,the fibers have diameters ranging
from about 500 nm to about 25 wm or from about 1 ym to
about 25 um or from about 1 um to about 100 um. In some
embodiments, the fibers have diameters ofless than about 100
nm. In some embodiments, the fibers contain pores. In some
embodiments, the entire fiber is substantially porous. In other
embodiments, a portion of the fiber contains pores and the
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remainder of the fiber does not contain pores. In some
embodiments,the exterior ofthe fiber contains pores, and the
interior portionsofthe fiber are substantially non-porous.
In various embodiments, compositions of the present dis-
closure may be spun into fibers by an electrospinning tech-
nique. Electrospinning involves the introduction of an exter-
nal electrostatic field to a conducting fluid being extruded
through a needle. Whenthe electric field is in equilibrium
with the droplets being extruded through the needle, a sus-
pended conical droplet, also known as a Taylor cone, is
formed. Additional voltage causesthe electric field to exceed
the surface tension, thereby causing the droplet to become
unstable and resulting in the ejection of a tiny fluid jet from
the surface of the droplet. When the droplet contains a poly-
mer, as in the embodiments ofthe present disclosure, ejection
of the fluid jet results fiber formation. The elongated melt of
the fluid jet experiences a whipping motion that results in
polymerstretching during formation ofthe fibers. The fibers
are collected on a grounded target as they are formed. In
embodiments of the present disclosure, the fibers spun by
electrospinning typically have a porous morphology due to
phase separation of the biodegradable polymerfrom the sol-
vent during spinning Rapid solvent evaporation thereby
results in pore formation. Electrospinning apparatuses
capable offorming sheetsoffabric or free-standing papers of
the compositions of the present disclosure are commercially
available.
In embodiments wherein the nitric oxide-releasing mate-
rial is a diazeniumdiolate, the compositions of the present
disclosure may prove advantageous over those previously
described in the art. Diazentumdiolates function through a
proton-mediated release of NO under physiological condi-
tions. During NO release, the pH increases as a result of
amine formation, which reducesthe availability ofprotons to
initiate further production ofNO. Hence, the NO releaserate
ofdiazentumdiolatesis self-inhibited by increased pH,and to
maintain a relatively constant NO release rate, external pH
control generally needs to be performed. Furthermore, with-
out pH regulation, only a small fraction of the theoretical
amount ofNO is produced.
Embodiments of the present disclosure advantageously
overcomethe self-inhibiting properties of diazentumdiolates
to afford a more constant NO release rate. In various embodi-
ments ofthe present disclosure, the biodegradable polymeris
hydrolysable in an aqueous solution, and a monomerpro-
duced by the hydrolysis of the biodegradable polymer is
operable for buffering the aqueous solution. For example, in
various embodiments of the present disclosure, the biode-
gradable polymer poly(lactic acid) hydrolysesto lactic acid.
Lactic acid, in turn, can neutralize amines formed from the
diazeniumdiolate, thereby buffering the aqueoussolution at a
pH more amenable for further NO release. Embodiments
herein mayalso be effective at mitigating the toxic effects of
diazeniumdiolate N-nitrosamine metabolic products.
FIG. 2 showsanillustrative schematic demonstrating the
manner in which poly(lactic acid) may buffer an aqueous
solution during nitric oxide release from a diazeniumdiolate.
As shownin FIG.2, a porous poly(lactic acid) fiber 1 may be
impregnated a diazeniumdiolate in order to encapsulate the
diazeniumdiolate. A fiber 2 containing encapsulated diazeni-
umdiolate is formed. Encapsulating may involve annealing or
coating fiber 2 after impregnating fiber 1 with the diazenium-
diolate. After encapsulating, at least a portion of the diazeni-
umdiolate is located within the pores of the fiber 2. The
diazeniumdiolate contained within the pores constitutes
many independent reservoirs of the nitric oxide-releasing
material that are encapsulated by the poly(lactic acid) poly-
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mer. As shownin FIG.2, uponhydrolysis ofpolymer3, acidic
monomers4 are released which decrease the pH and buffer
the solution within the pore. Concurrently, as polymer3 is
hydrolyzed, the diazentumdiolate is exposed to protic condi-
tions, resulting in NO and aminerelease. As further polymer
3 is hydrolyzed, more acidic monomers 4 are released to
neutralize the amines produced. Since each pore serves as an
independent reservoir of the diazeniumdiolate, NO release
can be significantly prolonged beyondthat typically observed
in the absence of a polymer.
Tt should be understoodthat the buffering mechanism pro-
posed in FIG. 2 is mechanistically non-limiting and repre-
sents Applicants’ current understanding of the process by
whichNO is produced. Further, one ofordinary skill in the art
will recognize that other nitric oxide-releasing materials may
be substituted for a diazeniumdiolate in the embodiments
described herein without departing from the spirit and scope
ofthe present disclosure.
Like the diazeniumdiolates described hereinabove, in
some embodimentsofthe present disclosure,at least a portion
of the zeolites, metal-organic frameworks or other porous
materials containing nitric oxide may be located within the
pores ofa biodegradable polymerfiber. In additional embodi-
ments, the zeolite or metal-organic frameworks may bedis-
persed uniformly throughout the biodegradable polymer in
the compositions described herein. In some embodiments,the
pores of a biodegradable polymerfiber form a tortuous path-
way connecting at least a portion of the zeolites.
Combining a biodegradable polymerwith a zeolite, metal-
organic framework or other porous material containing nitric
oxide introduces an ability to tune the nitric oxide release
characteristics through tailoring the porous morphology of
the fiber. For example, in various embodiments ofthe present
disclosure, the fiber may be annealed by heating so as to
reduce the porosity of the fiber. Annealing may reduce the
porosity of the interior portions of the fiber. Nitric oxide
release characteristics may also be altered by modifying at
least one property of the encapsulated zeolites including, for
example, zeolite type, exchanged cation and zeolite channel
diameter. Likewise, nitric oxide release may be modified by
using various types of metal-organic frameworks or other
porous materials identified hereinabove. In some embodi-
ments of the present compositions, the nitric oxide release
rate may be modified by coating the biodegradable polymer
with a polymer layer that does not contain the nitric oxide-
releasing material. FIG. 3A showsan illustrative schematic of
a standard electrospinning process in which a nitric oxide-
releasing material is dispersed in the biodegradable polymer.
FIG. 3B showsanillustrative schematic of a concentric elec-
trospinning process in which an interior fiber containing a
biodegradable polymeranda nitric oxide-releasing material
is coated with a polymerlayer not containing thenitric oxide-
releasing material. By controlling the thickness and identity
of the polymerlayer in the concentric electrospinning pro-
cess, nitric oxide release rates may be adjusted as required by
a particular application. In some embodiments, the polymer
layer may be a biodegradable polymer that is the same or
different than the biodegradable polymercontaining thenitric
oxide-releasing material.
Concentrations of the zeolite or metal-organic framework
in the biodegradable polymerare only limited by the appara-
tus used for spinning fibers of the compositions described
herein. High concentrations of zeolite or metal-organic
framework in the biodegradable polymer may interfere with
fiber formation. However, such operational limitations may
be overcome through use of industrial scale fiber-spinning
apparatuses, and all concentrations of porous materials
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within the fibers lie within the spirit and scope of the present
disclosure. In some embodiments, a concentration ofthe zeo-
lite in the biodegradable polymeris less than about 0.13
gramsof zeolite per gram of biodegradable polymer.
In other various embodiments of the present disclosure,
compositions for controlled release of nitric oxide include a
biodegradable polymer anda nitric oxide-releasing material
at least partially encapsulated by the biodegradable polymer.
The nitric oxide-releasing material is nitric oxide contained
within a porous material. The porous material may be, for
example, a zeolite, a metal-organic framework, or a mesopo-
rous molecular sieve. In some embodiments, the composi-
tions release nitric oxide for at least about 6 hours. In other
embodiments, the compositions release nitric oxide for at
least about 3 hours,or at least about 12 hours,or at least about
24 hours, or at least about 48 hours. In some embodiments,
the compositionsrelease nitric oxide for more than 48 hours.
In some embodiments, the biodegradable polymer is spun
into fibers and the fibers have been annealed so as to reduce
their porosity. Such annealing may enable more prolonged
nitric oxide release.
Compositions of the present disclosure may be included
with medical devices. In some embodiments of the medical
devices, the nitric oxide-releasing material of the composi-
tion is a diazeniumdiolate. In other embodiments ofthe medi-
cal devices,the nitric oxide-releasing material ofthe compo-
sition is nitric oxide contained within a zeolite. In still other
embodiments ofthe medical devices, the composition is nitric
oxide contained within a metal-organic framework. In some
embodiments, the composition coats the surface ofthe medi-
cal device. In such embodiments, the medical device may be
implanted in a tissue or specifically placed externally in order
to deliver its nitric oxide in a specific manner. The medical
devices of the present disclosure may be manufactured from
a material such as, for example, metal, glass, ceramic, fabrics
and polymers upon or with which the compositions described
herein may be deposited or admixed.
Medical devices of the present disclosure includestents,
vascular grafts, pacemaker leads, heart valves, electrodes,
sensors, trocars, guide wires, catheters, ocular lenses, sling
materials, sutures, wound dressings and bandages, blood col-
lection bags and storage tubes, tubing for bloodtransfusions
and hemodialysis, diabetic socks and bedding. In some
embodiments, the medical device is a bandage or wrap. In
some embodiments, the medical device is a textile.
In general, the compositionsofthe present disclosure may
be spun intofibers and incorporated into varioustextiles for a
numberof end uses. In some embodiments, the device is a
textile used for donor organ preservation. In some embodi-
ments, diabetic socks capable ofreleasing nitric oxide may be
used to improve circulation in diabetic patients. In some
embodiments, bedding capable of releasing nitric oxide may
be usedto aid in the prevention of bed sores.
Medical devices of the present disclosure may be used
externally or internally. Illustrative external uses for medical
devices and articles containing the compositions of the
present disclosure include, for example, hair growth,
increased circulation and donororgan preservation. Asa first
example, a hat may include the compositions of the present
disclosure in order to release nitric oxide to the scalp to
stimulate hair growth. The topical hair loss medication
minoxidil is a potent vasodilator. Compositionsofthe present
disclosure may function in a similar manner by releasing
nitric oxide to the scalp. Likewise, diabetic socks, textiles,
and other articles of clothing may be used to provide nitric
oxide to the skin. Diabetic patients are particularly known to
have poorcirculation and low nitric oxide levels, and diabetic
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socks and otherarticles of clothing containing the composi-
tions described herein may bebeneficial in treating these and
other patients having poor circulation. As previously men-
tioned,textiles containing compositions ofthe present disclo-
sure may be used to wrap an organ for preservation during
transplant operations.
Other embodiments of the invention utilize electrospun
fibers formed from compositions of the invention in textiles
and fabrics that could used in items like handkerchiefs, bed-
sheets and the like, which maybeuseto delivernitric oxide to
a patient.
In some embodiments, medical devices of the present dis-
closure may be usedfor either short-term or long-term release
of nitric oxide. For example, some cardiovascular applica-
tions may require a high NO release rate immediately after a
stent or vascular graft is implanted, followed by a sustained,
lower NO release rate thereafter. In other embodiments, a
sustained low level ofNO release maybe preferred, however.
Compositions of the present disclosure may be specifically
tailored to meeteither of these types ofNO releasecriteria.
Medical devices of the present disclosure may be used to
treat, mediate or prevent a variety of diseases in whichnitric
oxide is implicated as having a functionalrole. Such diseases
include, for example, infection, diabetic neuropathy, hyper-
tension, sexual dysfunction, cancer, deep vein thrombosis,
tendinopathy, and Duchenne muscular dystrophy. In some
embodiments, the compositions and medical devices of the
present disclosure may replace or be used in combination
with traditional anti-coagulant drugs and therapies.
Benefits of the compositions described herein are embod-
ied by nitric oxide-releasing bandages. Preliminary studies
on isolated rat hearts have demonstrated increased coronary
flow upon exposure to a bandage containing the nitric-oxide
releasing materials of the present disclosure.
In other various embodiments, methodsforpreparing com-
positions for controlled release of nitric oxide are described
herein. The methodsinclude providing a polymersolution of
a biodegradable polymerdissolved in a solvent; dispersing a
nitric oxide-releasing material into the polymersolution; and
electrospinning the polymer solution into a fiber containing
pores. For example, in some embodiments, the nitric oxide
releasing material is a diazeniumdiolate. In some embodi-
ments, the methods further include annealing the fiber by
heating. Such annealing may be used to densify the porous
structure ofthe fibers and further encapsulate the nitric oxide-
releasing material contained therein, thereby prolonging the
NOrelease time.
In other various embodiments of methods for preparing
compositions for controlled release ofnitric oxide, the meth-
ods include providing a polymersolution of a biodegradable
polymerdissolved in a solvent; dispersing a porous material
in the polymersolution; electrospinning the polymersolution
into a fiber containing pores; and impregnating the porous
material with nitric oxide. The porous material may be, for
example, a zeolite, a metal-organic framework, or mesopo-
rous molecular sieve. In some embodiments, the methods
further include annealing the fiber by heating after impreg-
nating the porous material with nitric oxide.
Experimental Examples
The following examples are provided to more fully illus-
trate some of the embodiments disclosed hereinabove. It
should be appreciated by those of ordinary skill in the art that
the techniques disclosed in the examples that follow repre-
sents techniquesthat constitute illustrative modesfor practice
of the disclosure. Those of ordinary skill in the art should, in
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light of the present disclosure, appreciate that many changes
can be madein the specific embodiments that are disclosed
and still obtain a like or similar result without departing from
the spirit and scope ofthe disclosure.
Example 1
Preparation of a Fiber Containing
Diazeneiumdiolates
Porous poly(lactic acid) polymerfibers containing a diaz-
eniumdiolate were prepared by electrospinning. High
molecular weight poly(lactic acid) (~100 kDa) was dispersed
in chloroform at room temperature at a concentration of
7-10% w/w to produce a viscous polymersolution. A diaz-
eniumdiolate was then introduced into the polymersolution
in varying quantities. Electrospinning wasthereafter initiated
by feeding the polymersolution into a syringe containing an
attached 18 to 22 gauge needle. A flow rate of 1 mL/hr was
used. A voltage of 15-20 kV wasapplied to the needle using
a variable high voltage power supply during electrospinning.
Aligned fibers containing the diazeniumdiolate were
obtained by using a groundedrotating drum positioned a
distance of 25 cm from the needle tip. A flat piece of alumi-
num foil (15 cmx15 cm) was used for collecting random
fibers.
Example 2
Synthesis of Zeolite-A and Nanoscale Zeolite-A
Sodium hydroxide (0.723 g) wasfirst dissolved in 80mL of
DI water andthen dividedinto two equal portions. Onehalfof
the sodium hydroxide solution was combined with sodium
aluminate (8.258 g) and stirred at room temperature (RT)
until clear. The secondhalfofthe sodium hydroxide solution
was mixed with sodium metasilicate (15.48 g) at RT until a
clear solution resulted. These clear solutions were then com-
bined withstirring at RT, resulting in a thick white gel. The gel
wasfurther stirred until homogenousandthen transferred to
a 150 mL polypropylene bottle before being subsequently
heated for 24 h at 90° C. The resulting white precipitate was
washed repeatedly with 10 mL aliquots of deionized water
and isolated through centrifugation.
Nanoscale Zeolite-A was synthesized as follows: Alumi-
num isopropoxide (0.75 g), trimethyl ammonium hydroxide
(5.0 g), 1 M sodium hydroxide solution (0.58 mL) and 7 mL
of DI water were stirred together until clear in a polypropy-
lene bottle at 40° C. In a separate polypropylenebottle, 30%
silica sol (2.25 g) was combined with 2.0 mL ofDI water and
stirred under at 40° C. until clear. The solutions were then
combined and placed in an oven for 24 h at 80° C. The
resulting solution was a suspension of zeolite nanoparticles,
which was washed repeatedly with a water/ethanol] mixture
and isolated by centrifugation. After repeated washings and
centrifugation ofthe solution,the zeolites eventually became
visible as a white precipitate. When the white precipitate
formed, several more washes and centrifugations were per-
formed to separate the zeolite from the supernatant liquid.
Dryingofthe isolated zeolite was conducted overnightat 90°
C. under reducedpressure.
Example 3
Preparation of Cobalt (II)-Exchanged Zeolite-A and
Cobalt (II)-Exchanged Nanoscale Zeolite-A
Cobalt (I])-exchanged zeolite A was prepared by combin-
ing Zeolite-A (1 g) ina 0.05 M solution of cobalt (IT) acetate
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(100 mL) with stirring at RT for at least 24 hours. The zeolite
was isolated through centrifugation, followed by two more
washing and centrifugation steps before the cobalt (II)-ex-
changed Zeolite-A was dried overnight at 80-90° C. under
reduced pressure. Elemental analysis of the cobalt (II)-ex-
changed Zeolite-A by ICP showed 9.27 wt. % cobalt. Both
cobalt (II-exchanged Zeolite-A and cobalt (II)-exchanged
nanoscale Zeolite-A were prepared by the aforesaid method.
FIG. 4A showsan illustrative SEM image of cobalt (1I)-
exchanged Zeolite-A. FIG. 4B showsan illustrative SEM
imageofcobalt (II)-exchanged nanoscale Zeolite-A. As dem-
onstrated from FIGS. 4A and 4B,cobalt (1])-exchanged Zeo-
lite-A had particle sizes ranging from ~1-2 um, whereas
cobalt (II)-exchanged nanoscale Zeolite-A had particle sizes
averaging ~100 nm.Both cobalt (I])-exchanged zeolites were
dark blue wheninfused with NO.The dark blue color faded to
pink upon exposureofthe NO-loadedzeolites to atmospheric
moisture. NO release rates of the zeolites are considered in
more detail hereinbelow.
Example 4
Preparation of a Fiber Containing Cobalt
(II)-Exchanged Zeolite-A
Aligned porouspoly(lactic acid) polymerfibers containing
cobalt (Il)-exchanged Zeolite-A were prepared by electro-
spinning A solution of 1.50 g ofpoly(lactic acid) in 10 mL of
dry chloroform wasfirst prepared. Thereafter, a dry powder of
cobalt (II)-exchanged Zeolite-A (0.2 g) was sonicated in 500
mL of chloroform until the zeolite crystals were well dis-
persed. This suspension was then mixed with the above poly
(lactic acid) solution with stirring, resulting in a blue viscous
polymersolution. The viscous solution was then fed through
a 20-gauge needle at a rate of 0.20-0.25 mL/h. To initiate
electrospinning, a voltage of 10 kV was applied to the needle
using a variable high voltage power supply. Aligned fibers
were collected using a groundedrotating drum covered with
aluminum foil positioned at a distance of 20 cm from the
needle tip. FIG. 5 showsan illustrative SEM imageofa cobalt
(II)-exchanged Zeolite-A-containing fiber. The porousstruc-
ture ofthe electrospunfiberis clearly observable in the image.
FIG.5 also showsthat a few of the zeolite crystals migrate to
the surface of the fiber. FIG. 6 showsanillustrative EDAX
silicon map showing that the zeolite particles are well dis-
persed throughoutthe cobalt (II])-exchanged Zeolite-A-con-
taining fiber with little to no particle aggregation. In FIG.6,
concentrated brighter areas correspond to detected silicon,
whichis diagnostic ofthe zeolite. FIG. 7 showsan illustrative
image of a bandage formed from a plurality of cobalt (II)-
exchanged Zeolite-A-containing fibers. Comparable results
were obtained from fibers containing cobalt (II)-exchanged
nanoscale Zeolite-A, although such fibers were somewhat
moreproneto zeolite aggregation within thefiber, resulting in
beaded fibers in somecases.
Example 5
Nitric Oxide Loading of Cobalt (II)-Exchanged
Zeolite-A
After electrospinning, the fibers containing cobalt (I])-ex-
changed Zeolite-A were placed in a pressure vessel and dried
at approximately 40° C. overnight under vacuum in an oven.
Bluish fibers were obtained. The pressure vessel was then
purged with argon for 15-20 minutes, and thefibers were then
exposed to nitric oxide (4 atm) for 1 hour. The excess nitric
20
25
30
40
45
55
60
14
oxide was removed, and the pressure vessel was again purged
with argon thereafter. Fibers containing cobalt (I])-ex-
changed Zeolite-A were charged with nitric oxide in a similar
manner. The bare cobalt (I])-exchanged Zeolite-A was loaded
with nitric oxide similarly, except the zeolite was dried under
vacuum overnight at 90° C. prior to loading.
Example 6
Annealing of NO-Loaded Fibers Containing Cobalt
(II)-Exchanged Zeolite-A
After being loaded with NO,the fibers from Example 5
were immediately placed in an oven at 65° C. for 30 minutes,
followed by 10 minutes of cooling to RT. This process was
repeatedthree times. After the last heating cycle, the pressure
vessel was again purged with argon to expel any excess or
desorbednitric oxide resulting from annealing. FIG. 8 shows
an illustrative cross-sectional SEM image of a cobalt (II)-
exchanged Zeolite-A-containing fiber following NO loading
and annealing. The porous structure of the fiber exterior
remains clearly observable in the image, but the inner pores
were observed to be coalesced and densified by the annealing
process. In contrast, a cross-sectional SEM image obtained
after freeze fracturing ofa non-annealed fiber clearly showed
the presence of an internal pore structure.
Example 7
Quantification ofNO Release from Cobalt (II)-Ex-
changed Zeolite-A, Non-Annealed Porous Fibers
Containing Cobalt (I])-Exchanged Zeolite-A, and
Annealed Fibers Containing Cobalt (II)-Exchanged
Zeolite-A
All samples were quantified for NO release immediately
afterNO infusion or following annealing. Nitric oxide release
wasstimulated by exposing the sample to a moisture-rich gas
flow. Constant relative humidity was achieved by passing an
argon flow through a saturated solution of magnesium chlo-
ride before exposure to the sample. This gas flow maintained
a constant 33% relative humidity. The flow rate was 180
cc/min. The evolved NO wascarried by the argon gas into a
vessel containing 10 mL of deionized water, where nitric
oxide reacted to form nitrite ions. NO quantification was
conducted by analyzing for producednitrite using the Griess
Reagent.
Cobalt (I)-Exchanged Zeolite-A:
FIG. 9A shows an illustrative NO release profile from
NO-loaded cobalt (I])-exchanged Zeolite-A. FIG. 9B shows
an illustrative NO releaseprofile from NO-loaded cobalt (I])-
exchanged nanoscale Zeolite-A. FIGS. 9A and 9B show that
most of the NO contained within the zeolites was released
within the first 100 seconds following exposure to moisture.
As determined from the NO release profiles, the NO loading
capacity of cobalt (I])-exchanged Zeolite-A was 0.774 mmol
NO/g zeolite, and for the cobalt (])-exchanged nanoscale
Zeolite-A the NO loading capacity was ~0.85 to 0.90 mmol
NO/g zeolite.
Non-Annealed, Porous Fibers Containing Cobalt (1])-Ex-
changed Zeolite-A:
FIG. 10 showsillustrative NO release profiles from non-
annealed, porousfibers containing cobalt (II) exchanged Zeo-
lite-A 10 and cobalt (II) exchanged nanoscale Zeolite-A 11.
The NO release profiles in both cases were similar to the free
zeolites, with most of the NO being released duringthefirst
100 seconds following exposure to moisture. Although the
US 9,216,198 B2
15
NOrelease profiles were not significantly altered for the
non-annealed, porous fibers, the presence of the polymer
binder places the nitric oxide-releasing material in a form
more compatible for biological and medical device applica-
tions.
The NOstorage capacity ofthe cobalt (II)-exchanged Zeo-
lite-A in the fibers was slightly lower than that of the corre-
sponding free zeolite without the polymer (0.55 mmol
NO/gram zeolite versus 0.775 mmol NO/gram zeolite for
cobalt (II)-exchanged Zeolite-A and 0.75 mmol NO/gram
zeolite versus ~0.85 mmol NO/gram zeolite for cobalt (II)
exchanged nanoscale Zeolite-A). The reduced NO storage
capacity may have been a byproduct of the electrospinning
process or NO loading of the zeolites contained within the
polymerfiber.
Annealed Fibers Containing Cobalt (II)-Exchanged Zeo-
lite-A:
FIGS. 11A and 11B show illustrative NO release profiles
from annealed fibers containing cobalt (I])-exchanged Zeo-
lite-A 12 and cobalt (II)-exchanged nanoscale Zeolite-A 14,
each in comparison to non-annealed fibers 13 and 15 contain-
ing the same zeolite material. As shown in FIGS. 11A and
11B, annealing resulted in a considerably more prolonged
release ofNO from thefibers, as well as a slowerrate ofinitial
NOrelease. Although NO release was more prolonged in the
annealed fibers, overall NO loading was reduced. FIG. 12
shows a histogram showing an illustrative decrease in NO
loading in cobalt (II-exchanged Zeolite-A-containing fibers
annealed at 65° C. and 85° C. The NO loading dropped by
about 40% in the fibers annealed at 65° C., whereas the NO
loading dropped by about 75% when annealing was con-
ducted at 85° C.
Example 8
Synthesis of a Copper(II)
Biphenyl-4,4'-Dicarboxylic Acid Triethylenediamine
Metal-Organic Framework
Cu (II) metal-organic framework nanocrystals were syn-
thesized in gram quantities by modifying published proce-
dures to control the water content in the reaction mixture, to
reduce the synthesis time, and to improve reproducibility. In
atypical synthesis, a 100 mL ethanol solution containing 1.75
g (8.8 mmol) of copper (II) acetate monohydrate wasstirred
at room temperature until dissolved. Then, 30 g ofactivated 4
A (4-8 mesh) molecular sieves were added to the solution.
After drying for 1 h, the molecular sieves were removed and
the solution was capped for further use. A second solution
consisting of 1.05 g (9.20 mmol) of triethylenediamine
(TED) in 90 mL oftoluene wasdried with 10 g of activated 4
A (4-8 mesh) molecular sieves. After drying for 1 h, the
molecular sieves were removed.Athird solution made of2.00
g (8.60 mmol) of bipheny]-4,4'-dicarboxylic acid (BPDA)
and 2.6 mL of formic acid in 200 mL of DMFwasheated to
110° C. ina 500 mL round bottom flask until the BPDA was
dissolved. The solution was then cooled to room temperature.
To removethe excess ofwater introduced by the formic acid,
1.5 g of activated 4 A(4-8 mesh) molecular sieves was added
to the solution. After drying for 1 h, the molecular sieves were
removed andthe solution wasrefluxed at 110° C. with strong
agitation until the BPDA dissolved. Once the DMF solution
reached 110° C., the ethanol solution was addedall at once
and was immediately followed by addition of the toluene
solution. Thefinal solution was heated to 110° C. with reflux-
ing and stirring for 30 h with the condenser open to atmo-
sphere. The resulting blue solution was then cooled to room
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temperature. Nanocrystalline metal-organic framework
material obtained byfiltering the blue solution and thenwash-
ing the blue cake with 3x50 mL of DMF.The cake wasdried
for 1 d at 80° C. in a vacuum oven. Activated metal-organic
framework nanocrystals were obtained byfiltering and wash-
ing the cake with a continuousflow of3x50 mL each ofDMF,
CHC1,, acetone, and CHC, in that order. The activated mate-
rial was dried in a vacuum oven at 90° C. for 1 d and then
cooled to room temperature under a blanket of nitrogen
before being removed from the vacuum oven. Activated metal
organic framework nanocrystals (2.8 g) were recovered and
stored in a cappedvialfilled with nitrogen. FIG. 13 shows an
illustrative SEM image of as-synthesized copper(II) biphe-
nyl-4,4'-dicarboxylic acid triethylenediamine metal-organic
framework. BET surface areas of approximately 3000 m?/g
and a pore size of 0.9 nm were calculated by analysis of the
adsorption isotherms. Thermogravimetric analysis indicated
stability up to 300° C.
Example 9
Nitric Oxide Loading of Copper (I])
Biphenyl-4,4'-Dicarboxylic Acid Triethylenediamine
Metal-Organic Framework
Nitric oxide loading of the metal-organic framework
nanocrystals or fibers containing the metal-organic frame-
work nanocrystals were conducted similarly to that ofthe Co
(II)-exchanged Zeolite A. Briefly, the metal-organic frame-
work nanocrystals or fibers containing the metal-organic
framework nanocrystals were dehydrated in a pressure vessel
for 3 h at 60° C. under vacuum. The vessel was then purged
withAr flow for 30 minutes and then backfilled with 4 atm of
NOfor 1 hour. After 1 h, the vessel was again evacuated and
excess NO wasflushed out of the vessel by purging with Ar
for 1 h. Samples were kept in the pressure vessel until ready
to be used for analysis.
Example 10
Quantification ofNO Release from Fibers
Containing Copper(ID) Biphenyl-4,4'-Dicarboxylic
Acid Triethylenediamine Metal-Organic Framework
Nanocrystals
Fibers containing copper (II) biphenyl-4,4'-dicarboxylic
acid triethylenediamine metal-organic framework nanocrys-
tals were prepared by electrospinning similarly to the process
described in Example 4. FIG. 14 showsanillustrative SEM
image of a fiber containing copper (II) biphenyl-4,4'-dicar-
boxylic acid triethylenediamine metal-organic framework
nanocrystals. As shown in FIG. 14,the fibers containing the
metal-organic framework wassubstantially similar in appear-
anceto the fibers containing the zeolite.
Quantification of NO release was conducted using moist
Ar in a manner analogous to that described in Example 7,
except a saturated manganese chloride solution was used to
maintain 50% relative humidity. FIG. 15 showsillustrative
comparative NOreleaseprofiles for non-annealedfibers con-
taining copper (II) biphenyl-4,4'-dicarboxylic acid triethyl-
enediamine metal-organic framework nanocrystals 20 and
cobalt (I])-exchanged nanoscale Zeolite-A 21. As shown in
FIG.15, underthe conditionstested, the NO release capacity
for the metal-organic framework was about5 times that ofthe
cobalt (1])-exchanged nanoscale Zeolite-A. The NO storage
capacity of the metal-organic framework-containing fibers
was approximately 5 mmol NO/gram metal-organic frame-
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work. The higherNO storage capacity can be attributed to the
higher surface area present in the metal-organic framework
comparedto the zeolite. Nitric oxide release was complete in
about 40 minutes. Note that the fibers of FIG. 15 were non-
annealed, so the NO release rate was more rapid than was
observed for annealed fibers in FIGS. 11A and 11B.
Example 11
Influence of NO-Releasing Fibers on Rat Heart
Arterial Blood Flow
A bandagefabricated from fibers containing a nitric oxide-
releasing metal-organic framework waspreparedas outlined
above. After animal sacrifice, rat hearts were immediately
excised from the chest cavity and cannulated through the
aorta, where it was fastened with a silk tie. The heart was then
perfused at a constant hydrostatic pressure of 50 mm Hg with
Kreb’s buffer at 37° C., which was continually gassed with
95% O, and 5% CO,. After perfusion, the heart was placed in
a warmingjacket at 37° C. The buffer was flowed through the
coronary arteries and collected in a fraction collector at one-
minute intervals. Each fraction was then weighed to calculate
the coronary flow rate. Following establishmentofa baseline
flow rate for 20 minutes, the warming jacket was removed,
and a nitric oxide-releasing bandage was wrapped around the
heart. The warming jacket was subsequently reapplied. The
buffer flow was allowed to equilibrate for 10 minutes, and
fraction collection was then conducted as above. FIG. 16
showsa plot demonstrating an illustrative increase in coro-
nary flow following exposure ofthe heart to the nitric oxide-
releasing bandage. As shown in FIG. 16, the coronary flow
rate increased significantly after wrapping the heart with the
nitric oxide-releasing bandage.
From the foregoing description, one of ordinary skill in the
art can easily ascertain the essential characteristics of this
disclosure, and without departing from the spirit and scope
thereof, can make various changes and modifications to adapt
the disclosure to various usages and conditions. The embodi-
ments described hereinabove are meantto beillustrative only
and should not be taken as limiting ofthe scope ofthe disclo-
sure, which is defined in the following claims.
Whatis claimedis the following:
1. A composition for controlled release of nitric oxide,
comprising:
an aligned electrospun, porous fiber, wherein the fiber
comprises a porous biodegradable polymer that com-
prises pores; and a nitric oxide-releasing material that is
at least partially encapsulated by the biodegradable
polymer, wherein the nitric oxide-releasing materialis
located within the pores of the biodegradable polymer
fiber; and
a second polymer, wherein the second polymer forms a
layer overthefiber andwherein the secondpolymer does
not contain nitric oxide-releasing material.
2. The composition of claim 1, wherein the porous biode-
gradable polymeris poly(lactic acid).
3. The composition of claim 1, wherein the nitric oxide-
releasing material is a diazeniumdiolate.
4. The composition of claim 1, wherein the biodegradable
polymeris hydrolysable in an aqueoussolution; and
wherein a monomerproduced by hydrolysis of the biode-
gradable polymeris operable for buffering the aqueous
solution.
5. The composition of claim 1, wherein the nitric oxide-
releasing material comprises nitric oxide contained within a
zeolite.
10
15
20
25
30
35
40
45
50
18
6. The composition ofclaim 5, wherein the zeolite is cobalt
(II)-exchanged Zeolite-A.
7. The composition of claim 1,
wherein a plurality of the electrospun, porous fibers are
assembledinto a free-standing paper.
8. The composition of claim 7, wherein the fibers have
diameters between about 100 nm and about 25 um.
9. The composition of claim 1, wherein the nitric oxide-
releasing material is nitric oxide contained within a metal-
organic framework.
10. A medical device comprising the composition of claim
1.
11. The medical device of claim 10, wherein the nitric
oxide-releasing material is a diazeniumdiolate.
12. The medical device of claim 10, wherein the nitric
oxide-releasing material is nitric oxide contained within a
zeolite.
13. The medical device of claim 10, wherein the nitric
oxide-releasing material is nitric oxide contained within a
metal-organic framework.
14. The medical device of claim 10, wherein the composi-
tion coats the surface of the medical device.
15. The medical device of claim 10, wherein the medical
device is selected from the group consisting of stents, vascu-
lar grafts, pacemakerleads, heart valves, electrodes, sensors,
trocars, guide wires, catheters, ocular lenses, sling materials,
sutures, wounddressing and bandages, blood collection bags
and storage tubes, tubing for blood transfusions and hemodi-
alysis, diabetic socks, and bedding.
16. The medical device of claim 10, wherein the medical
deviceis a textile.
17. The medical device of claim 10, wherein the medical
device is a bandage.
18. A method for preparing a composition for controlled
release of nitric oxide, said method comprising:
a) providing a polymer solution comprising a biodegrad-
able polymerdissolvedin a solvent;
b) dispersing a nitric oxide-releasing material in the poly-
mersolution; and
c) electrospinning the polymer solution into an aligned
electrospun, porousfiber that contains pores anda nitric
oxide-releasing material thatis at least partially encap-
sulated by the biodegradable polymer, wherein nitric
oxide-releasing material is located within the pores of
the biodegradable polymerfiber; and
d) coating the aligned electrospun, porous fiber with a
polymerlayer, said polymer layer comprising a biode-
gradable polymer does not contain the nitric oxide-re-
leasing material.
19. The method of claim 18, wherein the nitric oxide-
releasing material is a diazeniumdiolate.
20. The method of claim 18, further comprising:
annealing the aligned electrospun, porousfiber by heating
prior to coating the aligned electrospun, porousfiber.
21. A method for preparing a composition for controlled
release of nitric oxide, said method comprising:
a) providing a polymer solution comprising a biodegrad-
able polymerdissolvedin a solvent;
b) dispersing a porous material in the polymersolution;
wherein the porous material is selected from the group
consisting of a zeolite and a metal-organic frame-
work;
c) electrospinning the polymersolution to form an aligned
electrospun, porous fiber that contains pores and said
porous materialthat is at least partially encapsulated by
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the biodegradable polymer, wherein porous materialis
located within the pores of the biodegradable polymer
fiber;
d) impregnating the porous material with nitric oxide; and
e) coating the aligned electrospun, porous fiber with a 5
polymerlayer, said polymer layer comprising a biode-
gradable polymer does not contain the nitric oxide-re-
leasing material.
22. The methodof claim 21, further comprising:
annealing the aligned electrospun, porousfiber by heating 10
after said impregnating step.
* * * * *
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